Separately, the WSJ reports that Rodman & Renshaw doesn't expect Afrezza to get another shot at approval for two years and estimates MNKD will need $150-200 million to get there.
afrezza, business, comtex, down, investors, la times, mannkinds, market, mnkd, news, not approved, price, shares, stock, trade, update, usfda, value
"MannKind (MNKD) is down after it said it is eliminating 41 percent of its staff, 179 employees, following notification from the U.S. Food and Drug Administration that it would not approve the company's experimental inhaled insuli
From FNNO.com, this is the Financial News Network. I’m Cleo
Stiller-Farrell and this is your Midweek Market Wrap Up. The British
Bankers’ Association, which has the supervisory role of setting the
influential Libor rates, announced that it would be willing to give up
its...
The Wall Street Journal reports that home prices showed their best year-to-date gains since 2005, up 5.9% through July, signaling the housing market's steady march toward recovery. Also from the Wall Street Journal, IBM (IBM) will increase its efforts to sell so-called cloud computing services...
CEO Marissa Mayer is bringing in some more new blood to Yahoo!, tapping Ken Goldman as the company's new Chief Financial Officer. Goldman's appointment will take effect on October 22nd.
Goldman served as CFO at his most recent employer, Fortinet, having worked at Siebel Systems, Sybase,...